Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation.
Steven DeitelzweigAmiee KangJenny JiangChuan GaoXuemei LuoNipun AtrejaStella HanDong ChengSaarusri R LoganathanGregory Yoke Hong LipPublished in: Journal of clinical medicine (2024)
These findings may aid physicians and patients in making informed decisions when considering a switch between apixaban and rivaroxaban.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- direct oral anticoagulants
- end stage renal disease
- heart failure
- chronic kidney disease
- ejection fraction
- percutaneous coronary intervention
- newly diagnosed
- prognostic factors
- acute coronary syndrome
- patient reported